Pharma News

Keep updating your pharma knowledge
22 Apr 2015

Teva Pharmaceutical offers to buy Mylan for $40.1 bn

Posted By

Israel’s Teva Pharmaceutical Tuesday launched an unsolicited bid to buy Mylan for $40.1 billion in a transaction that would create a behemoth in generic drugs.

Under the offer, Mylan shareholders would receive a premium of 37.7 percent compared with the Mylan stock price of $59.57 prior to its April 8 bid for Perrigo, Teva said.

Quick Look at the Facts and Figues

Mylan Teva Pharmaceutical Industrues
2014 Revenue $ 7.6 Billion $20.6 Billion
2014 Net Income $ 929.4 Million $ 3.1 Billion
HQ Netherland Ireland
Employees 30000 40000

What if the deal works: 

Combining Israel-based Teva, the world’s largest generic drug maker, with Mylan, the third largest, would create a company with nearly $30 billion in revenue and more than 400 drugs awaiting regulatory approval. Teva expects a merger would generate $2 billion in synergies and tax savings.

Leave a Reply

The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!